Regenerative biotechnology
Heterologous Natural Killer Cells
Heterologous Natural Killer cells pretreated with nivolumab for antitumor immunotherapy.
Therapy of heterologous Natural Killer cells pretreated with nivolumab that enhances the innate and adaptive immune response against tumor cells.
Composition
Heterologous Natural Killer cells with nivolumab.
Pharmaceutical form
Injectable solution.
Presentation
Monovette with 4 ml.
Therapeutic Properties
Antitumor cytotoxic activity through activation of NK cells and blockade of the PD-1 pathway, enhancing the immune response.
- Recognition of tumor cells.
- Induction of tumor apoptosis.
- Blockade of tumor immune evasion.
- Increased antitumor cytotoxicity.
- Innate immune activation.
- Stimulation of adaptive response.
- Reduction of tumor growth.
- Support in resistant neoplasms.
Mechanism of action & Clinical data
NK cells induce tumor cytotoxicity and, with PD-1 blockade, restore immune recognition of malignant cells.